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Studies have shown that polymorphisms located at positions  106 and approximately  2100 base pairs (5VALR2) in the regulatory
region of the aldose reductase gene are associated with susceptibility to microvascular complications in patients with diabetes. The aim was to
investigate the functional roles of these susceptibility alleles using an in vitro gene reporter assay. Susceptibility, neutral and protective
5VALR2/ 106 alleles were transfected into HepG2 cells and exposed to excess D-glucose (D-glucose at final concentrations 14 or 28 mmol/l).
Transcriptional activities were determined using a dual luciferase reporter gene assay. The ‘‘susceptibility alleles’’ Z 2 with C 106 had the
highest transcriptional activity when compared with the ‘‘protective’’ combination of Z+ 2 with C 106 alleles (58.7F 9.9 vs. 10.1F 0.7;
P< 0.0001). Those constructs with either the Z or Z 2 in combination with the C 106 allele had significantly higher transcriptional
activities when compared to those with the T 106 allele (Z/C 106, 37.4F 5.4 vs. Z/T 106 7.7F 1.6, P< 0.003; Z 2/C 106,
58.7F 9.9 vs. Z 2/T 106 10.9F 0.6, P< 0.0001). These results demonstrate that the Z 2/C 106 haplotype is associated with elevated
transcriptional activity of the aldose reductase gene. This in turn may explain the role of these polymorphisms in the susceptibility to diabetic
microvascular complications.D 2003 Elsevier B.V. All rights reserved.Keywords: Aldose reductase gene; Diabetic microvascular complication; Polyol pathway; Hyperglycaemia; Hypertonicity1. Introduction
It is becoming clear that there is a genetic as well as
hyperglycaemic component for the development of micro-
vascular complications in patients with either Type 1 or
Type 2 diabetes mellitus. Recent studies have shown that a
AC dinucleotide repeat microsatellite in the promoter region
of the aldose reductase gene (AKR1B1 or ALR2) are
associated with the susceptibility to microvascular compli-
cations in patients with either Type 1 or Type 2 diabetes
mellitus who have diverse ethnic origins [1–6]. ALR2 is the
first and rate-limiting enzyme of the polyol pathway and
converts glucose to sorbitol in an NADPH-dependent reac-
tion. Several studies have shown that the ALR2 mRNA and0925-4439/03/$ - see front matter D 2003 Elsevier B.V. All rights reserved.
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diabetic microvascular complications [7–10]. The Z 2
‘susceptibility’ allele (5VALR2) that is located 2.1 kilobase
(kb) upstream in the promoter region of ALR2 gene has
been shown to be linked with increased mRNA levels in
peripheral blood mononuclear cells (PBMC) of patients with
diabetic nephropathy and Type 1 diabetes mellitus [11].
Further, when PBMC of patients with nephropathy and
Type 1 diabetes mellitus are exposed to hyperglycaemia in
vitro for 5 days, there is a marked induction of ALR2
mRNA with those individuals with the Z 2 allele having
more than eightfold increase in expression. In marked
contrast, the PBMC of patients with Type 1 diabetes
mellitus and no complications after 20 years duration of
diabetes as well as normal healthy controls showed no
change in the expression of ALR2 when exposed to hyper-
glycaemia [12].
A C 106T substitution in the basal promoter region has
been shown to be associated with susceptibility to diabetic
Table 1
Number of recombinants for each haplotype
Haplotypes No. recombinants no. transfection
Z+2/C 5 2a
Z+2/T 3 2
Z/C 4 2
Z/T 3 2
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Z 2/C 106 combination is a higher risk susceptibility
haplotype for microvascular complications compared to
Z+ 2/T or, Z+ 2/C haplotypes although this has not been
confirmed in other studies [14,15]. The aim of this study was
to investigate the functional role of these susceptibility and
protective haplotypes using an in vitro gene reporter assay. Z 2/C 5 2
ZC/T 4 2
Z 4/C 3 2
Z 4/T 4 2
a Transfection was performed twice for each recombinant. Therefore,
each mean of transcription activity in luciferase assays was the number of
recombinants times two for each haplotype under normal, hyperglycaemic
and hypertonic conditions.2. Materials and methods
2.1. Cloning of the ALR2 promoter gene into the pGL3-
enhancer vectors
An aliquot of high molecular weight DNA that had
previously been typed for the 5VALR2/C 106T poly-
morphic sites were used as template to amplify the promoter
region of the ALR2 gene using Expand High Fidelity PCR
System (Roche, East Sussex, UK). The region from  2223
to + 60 was amplified with the amplimers 5V-CATA-
CGCGTGTGCAGGCCTGGGACTAAGGGAAG-3V and
5V-CGGCTCGAGTGAGCAGGAGACGGCTTGC-
CATGG-3Vcontaining MluI and XhoI restriction sites. The
following haplotypes were amplified: Z 2/C 106, Z 2/
T 106, Z + 2/C 106, Z + 2/T 106, Z/C 106, Z/
T 106, Z 4/C 106 and Z 4/T 106 (Fig. 1). The
products were cloned into the pCR-XL-TOPO vectors
(Invitrogen, The Netherlands) following the manufacturer’s
instruction. The inserts were excised by digesting with the
restriction endonuclease XhoI and MluI, which were then
subcloned into the XhoI and MluI sites of the pGL3-
enhancer luciferase reporter vectors (Promega, Southamp-
ton, UK), which lack a promoter sequence. The 5VALR2 and
C 106T sites were confirmed by microsatellite analysis for
the 5VALR2 site and digestion with BfaI for the C( 106)TFig. 1. Structure of the promoter region of the human aldose reductase gene. The (
kb upstream in the promoter region. Z+ 2, Z, Z 2 and Z 4 alleles are equal to
present in the basal promoter region. There are several osmotic response elementpolymorphism. In addition, both strands of the inserts of all
recombinants used in this study were sequenced to confirm
the haplotypes (MWG, Milton Keynes, UK). For each
haplotype, at least three separate recombinants were con-
structed and used in the following transfection and lucifer-
ase assays (Table 1).
2.2. Transfection assays using ALR2-luciferase constructs
The recombinant plasmids were purified using QIAGEN-
tip 100 columns (QIAGEN, Dorking, UK). HepG2 cells
(ECACC, Salisbury, UK) maintained in complete culture
medium, which contains Eagle’s minimal essential medium
supplemented with 10% feotal bovine serum (FBS), 2
mmol/l glutamine, 1% nonessential amino acids and suitable
antibiotics were used for transfection. The cells were seeded
at 106 per well of 24-well plates and cultured for 24 h until
80% confluent at 37 jC incubator. For each well, the
following mixture was prepared in a 1.5-ml microcentrifuge
tube, 675 ng of recombinant plasmid and 75 ng of pRL-TKAC)n dinucleotide repeat polymorphism region (5VALR2) is located at  2.1
(AC)25, (AC)24, (AC)23 and (AC)22 repeats. A C 106T polymorphism is
s (OREs) located between the 5VALR2 and C 106T sites.
Fig. 2. This graph shows the number of transfection and luciferase assays for the recombinants. For each individual recombinant, transfection was performed
twice. For a single transfection reaction, eight wells were prepared and divided into four groups in duplicate. Group A was the normal control. The cells in
groups B and C were stressed under hyperglycaemic conditions (final D-glucose concentration, 14 and 28 mmol/l respectively). Group D contained cells
exposed to hypertonic conditions (extra 50 mmol/l of NaCl). At the end of incubation, the cells were harvested, lysed and a luciferase assay was performed (see
Sections 2.2 and 2.3).
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culture medium without FBS to a final volume of 197.8 Al.
Then, 2.2 Al of the Tfx-20 reagent (Promega) was added to
make final volume of 200 Al at charge ratio 2:1. The tubes
were incubated at room temperature for 15 min and the 24-
well plates containing the HepG2 cells were removed from
the incubator and the medium aspirated and replaced by theFig. 3. The effect of the (AC)n repeats and C( 106)T polymorphisms on lucife
normalised by the activity of Renilla luciferase is presented as relative lucifer
transcriptional activities in a number of independent recombinants for each haploty
luciferase assays is shown under each bar for each haplotype. For each recombin
bar. Comparison of the relative luciferase activity in all haplotypes by one-way A
hoc Bonferroni test revealed significant differences between recombinants and the
Z 2/T 106; (b) P < 0.003 vs. Z+2/T 106, Z/T 106 and Z 4/T 106; (c)mixture in the 1.5-ml tubes. The plates were then returned to
the incubator for 1 h before each well was overlaid with 1
ml of the complete medium and the plates returned to the
incubator.
For each individual recombinant, transfection was per-
formed twice. For each time’s transfection (i.e. for each
single recombinant), eight wells were prepared and dividedrase transcription in the pGL3-enhancer vectors. Firefly luciferase activity
ase activity, which is expressed as meansF S.E. Each mean represented
pe under normal conditions. The number of recombinants, transfection and
ant, repeated transfection was performed and expressed as  2 under each
NOVA showed a statistically significant difference ( P < 0.0001). The post
differences were indicated as above. (a) P < 0.0001 vs. Z+2/C 106 and
P < 0.04 vs. Z/C 106; (d) P < 0.0001 vs. all others apart from Z/C 106.
Fig. 4. This shows the relative luciferase activity in recombinants with
either the C 106 or the T 106 allele in cells exposed to normal
conditions. There is a highly significantly increase in transcriptional activity
in recombinants containing the C 106 allele. Each mean represented
transcriptional activities for haplotypes containing either C 106 or
T 106 allele (Table 1).
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normal control. To either Group B or Group C, 9.2 or 18.4
Al of 20% D-glucose was added, respectively (final D-
glucose concentration, 14 and 28 mmol/l, respectively).
Group D contained cells exposed to hypertonic conditions
created by adding 50 mmol/l of NaCl to the culture medium
(Fig. 2). All plates were incubated for a further 20 h before
they were lysed using 100 Al of lysis buffer (Promega) and
the lysates were stored at  80 jC.
2.3. Luciferase assay
Luciferase activity was measured using Dual-luciferase
reporter assay system (Promega) in a MLX luminometerFig. 5. Effects of the (AC)n repeats and C/T 106 on luciferase transcription in the
or hypertonic (extra 50 mmol/l of NaCl) conditions. No significant difference in
hyperglycaemic or hypertonic conditions when compared to normal conditions for
number of independent recombinants for each haplotype under normal, hyperglyc
and luciferase assays is shown under bars for each haplotype. For each recombin(Dynex Technologies Inc., USA). The density was used to
determine the transcriptional activity. The relative activity
was defined as luciferase activity normalised by the activity
of the internal control (Renilla luciferase).
2.4. Statistical analysis
The data were expressed as the meansF standard error of
the mean (S.E.). Post hoc analysis was performed using the
nonparametric Bonferroni [5] to compare the relative lucif-
erase activities between different groups after analysis of
variance (ANOVA). The t-test was used to compare the
relative luciferase activity between two groups. A P value of
less than 0.05 was considered significant.3. Results
There was a highly significant difference in the luciferase
activities between all the recombinants when the transfected
HepG2 cells were grown under normal conditions when
analysed by one way ANOVA (P < 0.0001) (Fig. 3). The
reporter construct containing the Z 2/C 106 ALR2
alleles had the highest relative luciferase activity
(58.7F 9.9) among all the constructs. The relative luciferase
activity in the Z 2/C 106 ALR2 promoter (58.7F 9.9)
was higher than the activity in any of the other constructs:
Z + 2 /C  106 (10.1 F 0.7, P < 0.0001), Z /C  106
(37.4 F 5.4, P < 0.04), Z  4 /C  106 (21.5 F 6.6,
P < 0.001) and all those with the Z+ 2, Z, Z 2 and Z 4
together with the T 106 allele (P < 0.0001). There was
nearly a fivefold increase in transcriptional activity of thepGL3-enhancer vectors under hyperglycaemic (14 or 28 mmol/l D-glucose)
transcriptional activity was found when the cells were exposed to either
an individual haplotype. Each mean represented transcriptional activities in a
aemic or hypertonic conditions. The number of recombinants, transfection
ant, repeated transfection was performed and expressed as  2 under bars.
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to the Z+ 2/C 106 and Z+ 2/T 106 ‘‘protective haplo-
types’’. Indeed, these ‘‘protective haplotypes’’ had the
lowest luciferase activities (10.1F 0.7 and 10.2F 1.7, re-
spectively). The Z/C 106 ALR2 promoter construct had
the second highest luciferase activity (37.4F 5.4) and was
significantly different from the Z+ 2/C 106 ALR2 pro-
moter construct (10.1F 0.7, P < 0.0001) as well as the
following combinations; Z+ 2, Z, Z 2 and Z 4 with
the T 106 (P < 0.002). Furthermore, there was a highly
significant difference in the transcriptional activity of all
ALR2 haplotypes containing the C 106 allele compared to
those with the T 106 allele (27.4F 4.2 vs. 10.3F 3.1,
P < 0.0001) (Fig. 4).
When the HepG2 cells that had been transfected with the
ALR2 promoter region constructs were exposed to hyper-
tonicity, the transcriptional activities were increased in all
haplotypes (Fig. 4), but these were not statistically signifi-
cantly different when compared with normal conditions.
When the cells were exposed to hyperglycaemia, there were
no significant changes in luciferase activity for any of the
haplotypes (Fig. 5).4. Discussion
Several studies have suggested that the Z 2 and
C 106 alleles are associated with the microvascular com-
plications whilst the Z+ 2 and T 106 may be protective
factors [1–4,13,16–18]. To determine whether these hap-
lotypes have a functional role in modifying transcription of
the ALR2 gene, we cloned the promoter region containing
the various combinations of Z+ 2, Z 2, Z and Z 4 allele
(a risk allele in Japanese study) [5] with either the C 106
or T 106 alleles into the pGL3-enhancer vectors, respec-
tively. The HepG2 cell line was selected for the transfection
experiments as it has previously been shown that it
expresses ALR2 and this can be induced by stress following
transfection [19–22]. This was confirmed by studies in this
laboratory (data not shown). The results demonstrate that
the susceptibility haplotype Z 2/C 106 had the highest
relative transcriptional activity compared to all other hap-
lotypes. This strongly supports the previous genetic studies
showing that the Z 2/C 106 alleles and haplotype con-
tribute to the genetic background for diabetic microvascular
complications. These results also concur with previous
studies showing that the Z 2 allele is associated with
significantly higher ALR2 mRNA levels as well as enzyme
activity in those patients with nephropathy compared to
those with neutral or protective allelic combinations
[11,12,18]. Increased expression of the ALR2 gene has
been demonstrated in human retinal pigment epithelial cell
lines that are homozygous C 106 alleles compared to
those with the T 106 or heterozygous for these alleles
[23]. Our study showed that those recombinants with the
Z+ 2/T 106 and Z+ 2/C 106 haplotypes had the lowesttranscriptional activity of all. Thus, there is evidence that not
only the Z 2 allele, but also the C 106 together would be
risk factors for diabetic complications. This was supported
by previous studies that demonstrated that the Z 2 and
C 106 alleles are in strong linkage disequilibrium [4,13]
although there have been conflicting reports [14,15]. The
results from this study strongly support the suggestion that
the Z 2/C 106 is the susceptibility haplotype rather than
other combinations of alleles proposed by other studies. The
biological basis of the conflicting results is not clear.
Neamat-Allah et al. [14] have mentioned that variations in
haplotype frequencies and patterns cannot be ruled out as a
source of variability in the results. They also explained that
there may be more than one haplotype carrying the disease-
predisposing variant, leading to differences in the degree of
association of Z 2 haplotype with diabetic complications
in different study groups. Other possible explanations could
be that association studies have limitations such as sample
sizes, bias of populations, diagnosis criteria, and differences
in the ethnical backgrounds and methods of genotyping.
Therefore, collaborative studies throughout the world to
standardise methods for genotyping and clinical data anal-
ysis are needed.
The haplotype construction containing the Z/C 106 had
the second highest relative luciferase activity among all
recombinants. This may reflect the normal baseline level of
ALR2 expression as ‘Z’ is the most common allele in the
normal population. Those constructs containing the ‘‘pro-
tective allele’’ Z+ 2 with either the C 106 or T 106
allele had a lower transcription activity and this may
contribute to the mechanisms protecting cells from hyper-
glycaemia. In contrast, the ‘‘susceptibility allele’’ Z 2 with
the C 106 would lead to increased flux through the polyol
pathway thereby contributing to the metabolic and vascular
abnormalities and oxidative stress and development of the
diabetic complications. The exact mechanism for the higher
transcription in the Z 2/C haplotype is not clear. A
Japanese group also confirmed that the transcription of the
ALR2 gene is enhanced or suppressed by the number of
dinucleotide repeats although they claimed that the Z 4
allele has a highest transcription activity [5]. Other studies
also support a role for dinucleotide repeats on enhancing
transcriptional activities, such as the human type 1 collagen
alpha2 (COL1A2) gene [24] as well as the matrix metal-
loproteinase-9 gene both in human and mouse [25,26]. The
mechanism by which dinucleotide repeats upstream of
genes regulate transcription may be due to modification of
DNA conformation, DNA helical and backbone parameters,
DNA structures and stability [27,28]. For the C( 106)T
polymorphism, the plausible explanation is that this poly-
morphism is located in the basal promoter region of the
ALR2 gene and close to the CCAAT promoter element,
which is present between  98 and  94 and appears to be
functionally active [19]. In this study, they also demonstrat-
ed that the CCAAT motif is recognised by a nuclear factor
from the Hep G2 cells. Therefore, different alleles may
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factor binding activity and finally change the basal tran-
scriptional level of the ALR2 gene. The Z 2 allele may
enhance the increased transcriptional level of the ALR2
gene, which is with the C 106 allele because these two
alleles are tightly linked each other [4,13].
Our results have shown that the hyperglycaemic con-
ditions did not increase transcriptional activity in all
recombinants. Whilst the OREs were present in the inserts,
it is unclear where the glucose-response elements reside.
Further, the cells were only briefly exposed to hypergly-
caemia and this may be too short a period to increase the
ALR2 gene expression. A previous study in rat Schwann
cells exposed to hyperglycaemia also found no increase in
ALR2 mRNA although this study did not take into account
any possible role of polymorphisms within the rat ALR2
gene [29].
In conclusion, we have found that the susceptibility
Z 2/C 106 haplotype had a greater transcriptional activ-
ity when compared with any of the other possible haplo-
types. This finding strongly supports the role of this
haplotype in the development of diabetic microvascular
complications.References
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